Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AVED
MCID: ATX019
MIFTS: 44

Ataxia with Vitamin E Deficiency (AVED)

Categories: Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Ataxia with Vitamin E Deficiency

About this section

MalaCards integrated aliases for Ataxia with Vitamin E Deficiency:

Name: Ataxia with Vitamin E Deficiency 25 20 43 6 70
Ataxia with Isolated Vitamin E Deficiency 25 20 43
Familial Isolated Vitamin E Deficiency 25 20 43
Friedreich-Like Ataxia 25 20 43
Aved 25 20 43
Friedreich Ataxia Phenotype with Selective Vitamin E Deficiency 43
Friedreich-Like Ataxia with Selective Vitamin E Deficiency 20
Familial Isolated Deficiency of Vitamin E 20
Ataxia, with Vitamin E Deficiency 39
Isolated Vitamin E Deficiency 20
Five 43

Characteristics:

GeneReviews:

25
Penetrance Aved shows nearly complete penetrance in individuals who are homozygous or compound heterozygous for a ttpa pathogenic variant.

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Eye diseases Neuronal diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Ataxia with Vitamin E Deficiency

About this section
GARD : 20 Ataxia with vitamin E deficiency (AVED) is a progressive disease affecting motor control and movement. Symptoms of AVED include slurred speech ( dysarthria ), difficulty coordinating movements ( ataxia ), numbness in the hands and feet ( peripheral neuropathy ), and progressive leg weakness. Some affected individuals may experience vision loss due to damage to the back of the eye ( retinitis pigmentosa ). Symptoms typically begin during childhood or adolescence and worsen with age, resulting in the need for a wheelchair by early adulthood. AVED is caused by a mutation to the TTPA gene. When this gene is damaged, vitamin E cannot be distributed throughout the body. Vitamin E is important because it protects the cells of the neurological system (neurons) from dangerous molecules called free radicals. AVED is inherited in an autosomal recessive manner. Treatment for AVED includes vitamin E supplements, which will prevent AVED from developing if given before symptoms begin and may reverse some neurological symptoms if begun after AVED develops.

MalaCards based summary : Ataxia with Vitamin E Deficiency, also known as ataxia with isolated vitamin e deficiency, is related to ataxia with vitamin 3 deficiency and dystonia 11, myoclonic, and has symptoms including ataxia An important gene associated with Ataxia with Vitamin E Deficiency is TTPA (Alpha Tocopherol Transfer Protein). The drugs Latanoprost and Dronabinol have been mentioned in the context of this disorder. Affiliated tissues include liver, eye and bone, and related phenotypes are abnormal pyramidal sign and muscle weakness

MedlinePlus Genetics : 43 Ataxia with vitamin E deficiency is a disorder that impairs the body's ability to use vitamin E obtained from the diet. Vitamin E is an antioxidant, which means that it protects cells in the body from the damaging effects of unstable molecules called free radicals. A shortage (deficiency) of vitamin E can lead to neurological problems, such as difficulty coordinating movements (ataxia) and speech (dysarthria), loss of reflexes in the legs (lower limb areflexia), and a loss of sensation in the extremities (peripheral neuropathy). Some people with this condition have developed an eye disorder called retinitis pigmentosa that causes vision loss. Most people who have ataxia with vitamin E deficiency start to experience problems with movement between the ages of 5 and 15 years. The movement problems tend to worsen with age.

GeneReviews: NBK1241
Sources

Related Diseases for Ataxia with Vitamin E Deficiency

About this section

Diseases related to Ataxia with Vitamin E Deficiency via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 33)
# Related Disease Score Top Affiliating Genes
1 ataxia with vitamin 3 deficiency 11.6
2 dystonia 11, myoclonic 11.3
3 ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia 11.3
4 cerebellar ataxia, early-onset, with retained tendon reflexes 11.3
5 spastic ataxia, charlevoix-saguenay type 11.3
6 anemia, sideroblastic, and spinocerebellar ataxia 11.3
7 ataxia and polyneuropathy, adult-onset 10.7
8 friedreich ataxia 10.5
9 autosomal recessive disease 10.4
10 dystonia 10.3
11 spasticity 10.3
12 abetalipoproteinemia 10.2
13 cervical dystonia 10.2
14 autosomal recessive cerebellar ataxia 10.2
15 autosomal dominant cerebellar ataxia 10.2
16 sensory peripheral neuropathy 10.2
17 tremor 10.2
18 atrial standstill 1 10.1
19 macular degeneration, age-related, 1 10.1
20 polyneuropathy 10.1
21 alzheimer disease 10.1
22 retinitis pigmentosa 10.1
23 branchiootic syndrome 1 10.1
24 hereditary ataxia 10.1
25 neuroretinitis 10.1
26 retinitis 10.1
27 liver disease 10.1
28 peripheral nervous system disease 10.1
29 neuropathy 10.1
30 axonal neuropathy 10.0
31 cholestasis 10.0
32 hypolipoproteinemia 10.0
33 hypotonia 10.0

Graphical network of the top 20 diseases related to Ataxia with Vitamin E Deficiency:



Diseases related to Ataxia with Vitamin E Deficiency
Sources

Symptoms & Phenotypes for Ataxia with Vitamin E Deficiency

About this section

Human phenotypes related to Ataxia with Vitamin E Deficiency:

31 (show all 25)
# Description HPO Frequency HPO Source Accession
1 abnormal pyramidal sign 31 hallmark (90%) HP:0007256
2 muscle weakness 31 hallmark (90%) HP:0001324
3 areflexia 31 hallmark (90%) HP:0001284
4 scoliosis 31 frequent (33%) HP:0002650
5 nystagmus 31 frequent (33%) HP:0000639
6 dysarthria 31 frequent (33%) HP:0001260
7 gait disturbance 31 frequent (33%) HP:0001288
8 dysmetria 31 frequent (33%) HP:0001310
9 nyctalopia 31 frequent (33%) HP:0000662
10 sensory neuropathy 31 frequent (33%) HP:0000763
11 pes cavus 31 frequent (33%) HP:0001761
12 dysdiadochokinesis 31 frequent (33%) HP:0002075
13 tremor 31 occasional (7.5%) HP:0001337
14 diabetes mellitus 31 occasional (7.5%) HP:0000819
15 developmental regression 31 occasional (7.5%) HP:0002376
16 visual impairment 31 occasional (7.5%) HP:0000505
17 abnormality of retinal pigmentation 31 occasional (7.5%) HP:0007703
18 abnormality of visual evoked potentials 31 occasional (7.5%) HP:0000649
19 hypertonia 31 occasional (7.5%) HP:0001276
20 skeletal muscle atrophy 31 occasional (7.5%) HP:0003202
21 hypertrophic cardiomyopathy 31 occasional (7.5%) HP:0001639
22 hemiplegia/hemiparesis 31 occasional (7.5%) HP:0004374
23 arrhythmia 31 occasional (7.5%) HP:0011675
24 mental deterioration 31 occasional (7.5%) HP:0001268
25 dystonia 31 occasional (7.5%) HP:0001332

UMLS symptoms related to Ataxia with Vitamin E Deficiency:


ataxia
Sources

Drugs & Therapeutics for Ataxia with Vitamin E Deficiency

About this section

Drugs for Ataxia with Vitamin E Deficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1136)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
2
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
3
Lactitol Approved, Investigational Phase 4 585-86-4 157355
4
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
5
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
6
Phenol Approved, Experimental Phase 4 108-95-2 996
7
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
8
Eprosartan Approved Phase 4 133040-01-4 5281037
9
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
10
Trandolapril Approved Phase 4 87679-37-6 5484727
11
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
12
Ramipril Approved Phase 4 87333-19-5 5362129
13
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
14
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
15
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
16
Fosinopril Approved Phase 4 98048-97-6 55891
17
Enalaprilat Approved Phase 4 76420-72-9 6917719
18
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
19
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
20
Azilsartan medoxomil Approved, Investigational Phase 4 863031-21-4
21
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
22
Zofenopril Approved Phase 4 81872-10-8
23
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
24
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
25
Roxithromycin Approved, Investigational, Withdrawn Phase 4 80214-83-1 444037 6915744
26
Losartan Approved Phase 4 114798-26-4 3961
27
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
28
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
29
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
30
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
31
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
32
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
33
Citalopram Approved Phase 4 59729-33-8 2771
34
Metronidazole Approved Phase 4 443-48-1 4173
35
Iron Approved Phase 4 7439-89-6 23925 29936
36
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
37
Donepezil Approved Phase 4 120014-06-4 3152
38
Remifentanil Approved Phase 4 132875-61-7 60815
39
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
40
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
41
Nimesulide Approved, Investigational, Withdrawn Phase 4 51803-78-2 4495
42
Adapalene Approved Phase 4 106685-40-9 60164
43
Benzoyl peroxide Approved Phase 4 94-36-0 7187
44
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
45
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
46
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
47
Budesonide Approved Phase 4 51333-22-3 63006 5281004
48
carbamide peroxide Approved Phase 4 124-43-6
49
Petrolatum Approved, Investigational Phase 4 8009-03-8
50
Fenofibrate Approved Phase 4 49562-28-9 3339

Interventional clinical trials:

(show top 50) (show all 3548)
# Name Status NCT ID Phase Drugs
1 IntAct, Study on Promotion of Intrinsic Activity. Unknown status NCT00156741 Phase 4
2 Filgrastim for Treatment of Premature Ovarian Insufficiency: Randomized Clinical Trial Unknown status NCT02783937 Phase 4 Saline
3 The Effect of Far Infrared (FIR) Therapy on Access Flow of Arteriovenous (AV) Fistula, Echocardiographic Parameters and Endothelial Function in Patients With End Stage Renal Disease Unknown status NCT01138254 Phase 4
4 'A Prospective Randomized Trial to Assess the Impact of Ascorbic Acid on Outcomes and Complications Post Cardiac Surgeries'' Unknown status NCT03639519 Phase 4 Ascorbic Acid 500Mg Chew Tab
5 A Randomised Controlled Trial to Compare the Clinical Effectiveness of Selective Laser Trabeculoplasty (SLT) Versus Topical Therapy in the Treatment of Pseudoexfoliative Glaucoma Unknown status NCT01704989 Phase 4 Prostagladin
6 Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence Unknown status NCT02566928 Phase 4 2% mupirocin ointment
7 The Treatment of Periodontal Diseases. A Randomized, Blinded, Five Years Follow-up, Four-arm, Placebo Controlled Clinical Intervention Trial Unknown status NCT01318928 Phase 4 Metronidazol
8 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
9 A Five Year, Prospective, Randomized, Blinded, Controlled Trial Comparing the Efficacy of a Modified Diabetes Prevention Protocol and the Standard Comprehensive Outpatient Care in Lowering the Incidence of New Onset Diabetes Among People Treated for Schizophrenia and Are at Risk to Develop Type II Diabetes Mellitus. Unknown status NCT00182494 Phase 4
10 Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation：a Single-center Randomized Controlled Trial Unknown status NCT04209959 Phase 4 nifekalant
11 Effect of Perineural Dexmedetomidine on the ED50 Ropivacaine for Brachial Plexus Blocks in Pediatric Patients: a Randomized Trial Unknown status NCT02781246 Phase 4 perineural dexmedetomidine
12 Status of the Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis in Relation to Growth Failure, Body Weight and Neuroprotection in Children With Ataxia Telangiectasia Unknown status NCT01052623 Phase 4 Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
13 Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics? - A Pilot Study. Optional Deoxyribo-Nucleic Acid Donation for the Study of Hypertension. Unknown status NCT01715584 Phase 4
14 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
15 Double Blind, Placebo-Controlled Trial of THC as add-on Therapy for PTSD Unknown status NCT00965809 Phase 4 Tetrahydrocannabinol
16 The Efficacy and Safety of Nicotinic Acid in the Hemodialysis Patients With Hyperphosphatemia Unknown status NCT02836184 Phase 4 Nicotinic Acids;Calcium Carbonate
17 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
18 Comparison Between the Analgesic Affects of Tramadol® and "Verbal Anesthesia" on Pain Management Associated With the Insertion of Jaydess® in Nulliparous Women Unknown status NCT02706509 Phase 4 Tramadol
19 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Unknown status NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
20 Distribution and Expression of Non-neuronal Transient Receptor Potential (TRPV) Ion Channels in Sensitive Skin Syndrome. Unknown status NCT01871883 Phase 4
21 Effectiveness of the Lavage With 70% Alcohol Plus 0.5% Chlorhexidine Compared to 70% Alcohol for Chemical Matricectomy in the Surgical Treatment of Ingrown Toenails Unknown status NCT01844141 Phase 4 70% alcohol;70% alcohol - 0.5% clorhexidine
22 Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena, a Randomized Clinical Trial Unknown status NCT03186586 Phase 4 Ulipristal acetate;Placebo
23 Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome Unknown status NCT03148444 Phase 4 cefalexin 500 mg qid or roxithromycin 150 mg bid
24 SMARTDELAY Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy Completed NCT00677014 Phase 4
25 European Multicenter Study RF Versus Cryo in AVNRT: A Randomized Study Comparing Cryo-Energy vs. Radiofrequency-Energy Ablation Technique for AV Nodal Reentry Tachycardia (AVNRT) Completed NCT00196222 Phase 4
26 Factors of Treatment Response in Major Depressive Disorder Completed NCT00200902 Phase 4 Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)
27 Efficacy of Intravenous Lidocaine at Alleviating Pain Associated With Propofol Infusion in Pediatric Patients Undergoing Procedural Sedation Completed NCT00786916 Phase 4 normal saline;lidocaine;lidocaine
28 Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women Completed NCT01046578 Phase 4 Letrozole;Letrozole;Letrozole;Letrozole;Letrozole;Letrozole
29 A Comparison of Surgical Outcome Following Drug-induced Sleep Endoscopic Diagnosis Using Propofol or Dexmedetomidine for Sedation : A Prospective Randomized Trial Completed NCT01895348 Phase 4 Propofol;propofol-remifentanil;Dexmedetomidine-remifentanil
30 Cardioversion, Ablation or Pace and Ablate for Persistent Atrial Fibrillation in Over 65s - The CAPAPAF-65 Study Completed NCT02528604 Phase 4
31 Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump, Cetaphil® DermaControlâ„¢ Moisturizer SPF 30, and Cetaphil® DermaControlâ„¢ Foam Wash Regimen in Student Athletes With Mild to Moderate Acne Vulgaris Completed NCT02249104 Phase 4 Adapalene/benzoyl peroxide gel, 0.1%/2.5%
32 Acute and Chronic Effect of His-pacing in Consecutive Patients With AV-block Completed NCT01019213 Phase 4
33 Randomized Comparison Between Magnetically Navigated vs Manually Guided Radiofrequency in AV-node-reentry-tachycardia Completed NCT00875914 Phase 4
34 Prevention of Atrial Arrhythmia in Patients Without AV Conduction Disease Completed NCT01170611 Phase 4
35 XIENCE V® Everolimus Eluting Coronary Stent System USA Post- Approval Study (XIENCE V® USA DAPT Cohort) (XVU-AV DAPT) Completed NCT01106534 Phase 4 placebo + aspirin;clopidogrel + aspirin OR prasugrel + aspirin
36 Påskyndar PTH läkningen av Konservativt Behandlade Humerusfrakturer? Completed NCT01105832 Phase 4 Teriparatide
37 Study of Pain, Anxiety, Complications Related to AV Fistula Cannulation in Chronic Hemodialysis Patients. A. Buttonhole vs. Rope Ladder Technique B. Catheters With Cylindrical Point vs. Catheters With Bevel Point in Rope Ladder Technique Completed NCT00544492 Phase 4
38 Inhibition of Unnecessary RV Pacing With AV Search Hysteresis in ICDs Completed NCT00148967 Phase 4
39 Fluency Stent-Graft Versus Luminex Stent for Angioplasty of Recurrent Stenosis of the Cephalic Arch in Autogenous Arteriovenous (AV) Access for Hemodialysis Completed NCT00318435 Phase 4
40 Relapse Prevention With Varenicline Completed NCT00944554 Phase 4 Varenicline;Placebo
41 House Dust Mite Sublingual Immunotherapy: a Double-blind, Placebo Control Study in Elderly Patients. Completed NCT01605760 Phase 4 immunotherapy Staloral
42 Preemptive Local Anesthetic Infiltration Reduces Opioid Requirements Without Attenuation of the Intraoperative Evoked Stapedial Reflex Thresholds in Pediatric Cochlear Implant Surgery Completed NCT03721081 Phase 4 Lidocaine 1%/Epi 1:200000
43 The Effect of a PPAR Alpha Agonist on CYP Monooxygenase Activity in Humans Completed NCT00872599 Phase 4 fenofibrate;Placebo
44 Comparative Efficacy of Single-dose Doxycycline Versus Standard 5- Day Amoxicillin Treatment for Patients With Non-malarial Fever: a Randomized Non-inferiority Trial in Senegal Completed NCT03765931 Phase 4 Doxycycline;Amoxicillin
45 The Efficacy of Penile Rehabilitation Using Udenafil After Total Mesorectal Excision of Rectal Cancer Completed NCT01421940 Phase 4 Placebo drug;Udenafil
46 Double Blinded, Randomized Trial, Comparing Intravenous Bolus of 50 mg of Hydrocortisone Every 6 Hours for 7 Days With a Continuous Infusion of 300 mg Per Day of Hydrocortisone 300-mg Group During 5 Days in the Treatment of Septic Shock. Completed NCT02768740 Phase 4 Hydrocortisone hemisuccinate
47 Random, Phase IV, Multicentre, Double Blind, Placebo Controlled, Parallel Study to Assess Long-term Efficacy and Safety of Repeated Intraarticular Injections of Hyaluronic Acid (ADANT®) in Patients With Knee OA of the Knee Completed NCT00669032 Phase 4
48 A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Secukinumab on Aortic Vascular Inflammation and Cardiometabolic Biomarkers After 12 Weeks of Treatment, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completed NCT02690701 Phase 4 Secukinumab 300 mg
49 The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis Completed NCT02458729 Phase 4 Tranexamic Acid 5%,5ml/amp (intraoperative);Tranexamic Acid 5%,5ml/amp (3 hours after operation);0.9% Normal Saline (intraoperative);0.9% Normal Saline (3 hours after operation);rivaroxaban (10mg)
50 Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo

Search NIH Clinical Center for Ataxia with Vitamin E Deficiency

Sources

Genetic Tests for Ataxia with Vitamin E Deficiency

About this section
Sources

Anatomical Context for Ataxia with Vitamin E Deficiency

About this section

MalaCards organs/tissues related to Ataxia with Vitamin E Deficiency:

40
Liver, Eye, Bone, Endothelial, Skin, Breast, Brain
Sources

Publications for Ataxia with Vitamin E Deficiency

About this section

Articles related to Ataxia with Vitamin E Deficiency:

(show top 50) (show all 116)
# Title Authors PMID Year
1
Ataxia with Vitamin E Deficiency May Present with Cervical Dystonia. 61 25 6
27274910 2016
2
Ataxia with vitamin e deficiency in norway. 6 25 61
25614784 2015
3
Molecular, clinical and peripheral neuropathy study of Tunisian patients with ataxia with vitamin E deficiency. 6 25 61
24369383 2014
4
Vitamin E deficiency ataxia with (744 del A) mutation on alpha-TTP gene: genetic and clinical peculiarities in Moroccan patients. 6 25 61
15953402 2005
5
Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. 61 25 6
15300460 2004
6
Clinical comparison between AVED patients with 744 del A mutation and Friedreich ataxia with GAA expansion in 15 Moroccan families. 6 25 61
12039660 2002
7
Ataxia with isolated vitamin E deficiency: heterogeneity of mutations and phenotypic variability in a large number of families. 6 25 61
9463307 1998
8
The molecular basis of vitamin E retention: structure of human alpha-tocopherol transfer protein. 6 25
12899840 2003
9
Human alpha-tocopherol transfer protein: gene structure and mutations in familial vitamin E deficiency. 6 25
8602747 1996
10
Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein. 6 25
7719340 1995
11
Ataxia with vitamin E deficiency in southeast Norway, case report. 6 61
19566498 2009
12
Ataxia with vitamin E deficiency and severe dystonia: report of a case. 6 61
12907280 2003
13
A family with spinocerebellar ataxia type 8 expansion and vitamin E deficiency ataxia. 61 6
12470185 2002
14
Molecular and clinical study of a cohort of 110 Algerian patients with autosomal recessive ataxia. 6
26068213 2015
15
Normal spermatogenesis and sperm function in a subject affected by cerebellar ataxia due to congenital vitamin E deficiency. 6
23445347 2014
16
Epilepsy in a patient with ataxia caused by vitamin E deficiency. 6
22696689 2011
17
Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management. 25 61
19440741 2010
18
A novel delins mutation in the alpha-TTP gene in a family segregating ataxia with isolated vitamin E deficiency. 6
18458655 2008
19
Ataxia with vitamin E deficiency associated with deafness. 25 61
19102053 2008
20
Biochemical consequences of heritable mutations in the alpha-tocopherol transfer protein. 25 61
16819822 2006
21
Prevalence of inherited ataxias in the province of Padua, Italy. 61 25
15297793 2004
22
Crystal structure of human alpha-tocopherol transfer protein bound to its ligand: implications for ataxia with vitamin E deficiency. 25 61
14657365 2003
23
Effect of vitamin E supplementation in patients with ataxia with vitamin E deficiency. 25 61
11554913 2001
24
Ataxia with vitamin E deficiency: biochemical effects of malcompliance with vitamin E therapy. 25 61
11094124 2000
25
Ataxia caused by mutations in the alpha-tocopherol transfer protein gene. 25 61
10896705 2000
26
Ataxia with isolated vitamin E deficiency: a Japanese family carrying a novel mutation in the alpha-tocopherol transfer protein gene. 6
10360777 1999
27
Localization of alpha-tocopherol transfer protein in the brains of patients with ataxia with vitamin E deficiency and other oxidative stress related neurodegenerative disorders. 25 61
10082886 1999
28
Friedreich's ataxia with isolated vitamin E deficiency: a neuropathological study of a Tunisian patient. 25 61
9194904 1997
29
Can ACG serve as an initiation codon for protein synthesis in eucaryotic cells? 6
3837850 1985
30
Vitamin E is essential for Purkinje neuron integrity. 25
24342566 2014
31
Vitamin E. 25
22585906 2012
32
Hepatic α-tocopherol transfer protein: ligand-induced protection from proteasomal degradation. 25
20828164 2010
33
Mechanisms of genetically-based resistance to malaria. 25
20655368 2010
34
Alpha-tocopherol transfer protein disruption confers resistance to malarial infection in mice. 25
20403155 2010
35
alpha-Tocopherol transfer protein inhibition is effective in the prevention of cerebral malaria in mice. 25
19923370 2010
36
Molecular determinants of heritable vitamin E deficiency. 25
15065857 2004
37
Localization of alpha-tocopherol transfer protein in trophoblast, fetal capillaries' endothelium and amnion epithelium of human term placenta. 25
15190938 2004
38
Mutations in a novel gene encoding a CRAL-TRIO domain cause human Cayman ataxia and ataxia/dystonia in the jittery mouse. 25
14556008 2003
39
Human placental trophoblast cells express alpha-tocopherol transfer protein. 25
12744919 2003
40
Incorporation of deuterated RRR- or all-rac-alpha-tocopherol in plasma and tissues of alpha-tocopherol transfer protein--null mice. 25
11864863 2002
41
Urinary alpha-tocopherol metabolites in alpha-tocopherol transfer protein-deficient patients. 25
11013295 2000
42
A novel human tocopherol-associated protein: cloning, in vitro expression, and characterization. 25
10829015 2000
43
Postmortem study of ataxia with retinitis pigmentosa by mutation of the alpha-tocopherol transfer protein gene. 25
10727494 2000
44
Vitamin E deficiency due to chylomicron retention disease in Marinesco-Sjögren syndrome. 25
10665502 2000
45
Treatment of ataxia in isolated vitamin E deficiency caused by alpha-tocopherol transfer protein deficiency. 25
9931538 1999
46
Localization of alpha-tocopherol transfer protein in rat brain. 25
9855364 1998
47
Crystal structure of the Saccharomyces cerevisiae phosphatidylinositol-transfer protein. 25
9461221 1998
48
Effect of plasma alpha-tocopherol on leukotriene E4 excretion in genetic vitamin E deficiency. 25
9266396 1997
49
Affinity for alpha-tocopherol transfer protein as a determinant of the biological activities of vitamin E analogs. 25
9199513 1997
50
Ataxia with isolated vitamin E deficiency in four siblings. 25
8972536 1996
Sources

Variations for Ataxia with Vitamin E Deficiency

About this section

ClinVar genetic disease variations for Ataxia with Vitamin E Deficiency:

6 (show top 50) (show all 105)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TTPA NM_000370.3(TTPA):c.19del (p.Gln7fs) Deletion Pathogenic 208623 rs760014795 GRCh37: 8:63998562-63998562
GRCh38: 8:63086003-63086003
2 TTPA NM_000370.3(TTPA):c.205-1G>T SNV Pathogenic 267261 rs886040963 GRCh37: 8:63985648-63985648
GRCh38: 8:63073089-63073089
3 TTPA NM_000370.3(TTPA):c.552+2T>A SNV Pathogenic 267262 rs886040964 GRCh37: 8:63978461-63978461
GRCh38: 8:63065902-63065902
4 TTPA NM_000370.3(TTPA):c.191A>G (p.Asp64Gly) SNV Pathogenic 65590 rs397515523 GRCh37: 8:63998390-63998390
GRCh38: 8:63085831-63085831
5 TTPA NM_000370.3(TTPA):c.303T>G (p.His101Gln) SNV Pathogenic 9137 rs121917849 GRCh37: 8:63985549-63985549
GRCh38: 8:63072990-63072990
6 TTPA NM_000370.3(TTPA):c.421G>A (p.Glu141Lys) SNV Pathogenic 65592 rs397515524 GRCh37: 8:63978594-63978594
GRCh38: 8:63066035-63066035
7 TTPA NM_000370.3(TTPA):c.530_531delinsGTAAGT (p.Lys177fs) Indel Pathogenic 65595 rs1554605631 GRCh37: 8:63978484-63978485
GRCh38: 8:63065925-63065926
8 TTPA NM_000370.3(TTPA):c.548T>C (p.Leu183Pro) SNV Pathogenic 65596 rs397515525 GRCh37: 8:63978467-63978467
GRCh38: 8:63065908-63065908
9 TTPA NM_000370.3(TTPA):c.736G>C (p.Gly246Arg) SNV Pathogenic 65598 rs397515526 GRCh37: 8:63973912-63973912
GRCh38: 8:63061353-63061353
10 TTPA NM_000370.3(TTPA):c.513_514insTT (p.Thr172fs) Insertion Pathogenic 9139 rs397515379 GRCh37: 8:63978501-63978502
GRCh38: 8:63065942-63065943
11 TTPA NM_000370.3(TTPA):c.744del (p.Glu249fs) Deletion Pathogenic 9136 rs397515377 GRCh37: 8:63973904-63973904
GRCh38: 8:63061345-63061345
12 TTPA NM_000370.3(TTPA):c.400C>T (p.Arg134Ter) SNV Pathogenic/Likely pathogenic 9141 rs121917851 GRCh37: 8:63978615-63978615
GRCh38: 8:63066056-63066056
13 TTPA NM_000370.3(TTPA):c.487del (p.Trp163fs) Deletion Pathogenic/Likely pathogenic 188951 rs397515378 GRCh37: 8:63978528-63978528
GRCh38: 8:63065969-63065969
14 TTPA NM_000370.3(TTPA):c.205-1G>C SNV Pathogenic/Likely pathogenic 370407 rs886040963 GRCh37: 8:63985648-63985648
GRCh38: 8:63073089-63073089
15 TTPA NM_000370.3(TTPA):c.205-2A>G SNV Pathogenic/Likely pathogenic 370950 rs758349851 GRCh37: 8:63985649-63985649
GRCh38: 8:63073090-63073090
16 TTPA NM_000370.3(TTPA):c.2T>A (p.Met1Lys) SNV Likely pathogenic 371454 rs786204758 GRCh37: 8:63998579-63998579
GRCh38: 8:63086020-63086020
17 TTPA NM_000370.3(TTPA):c.552G>A (p.Thr184=) SNV Likely pathogenic 374211 rs181109321 GRCh37: 8:63978463-63978463
GRCh38: 8:63065904-63065904
18 TTPA NM_000370.3(TTPA):c.88_118del (p.Ala30fs) Deletion Likely pathogenic 550204 rs1554525125 GRCh37: 8:63998463-63998493
GRCh38: 8:63085904-63085934
19 TTPA NM_000370.3(TTPA):c.227_229delinsATT (p.Trp76_Arg77delinsTyrTer) Indel Likely pathogenic 551293 rs1554524061 GRCh37: 8:63985623-63985625
GRCh38: 8:63073064-63073066
20 TTPA NM_000370.3(TTPA):c.313A>T (p.Arg105Ter) SNV Likely pathogenic 370354 rs1057516423 GRCh37: 8:63985539-63985539
GRCh38: 8:63072980-63072980
21 TTPA NM_000370.3(TTPA):c.441del (p.Glu148fs) Deletion Likely pathogenic 371663 rs1057517448 GRCh37: 8:63978574-63978574
GRCh38: 8:63066015-63066015
22 TTPA NM_000370.3(TTPA):c.13C>T (p.Arg5Ter) SNV Likely pathogenic 370311 rs1008240677 GRCh37: 8:63998568-63998568
GRCh38: 8:63086009-63086009
23 TTPA NM_000370.3(TTPA):c.83_105del (p.Leu28fs) Deletion Likely pathogenic 558725 rs1554525128 GRCh37: 8:63998476-63998498
GRCh38: 8:63085917-63085939
24 TTPA NM_000370.3(TTPA):c.339del (p.Val114fs) Deletion Likely pathogenic 633013 rs1563363293 GRCh37: 8:63985513-63985513
GRCh38: 8:63072954-63072954
25 TTPA NM_000370.3(TTPA):c.172G>C (p.Ala58Pro) SNV Likely pathogenic 802413 rs982650476 GRCh37: 8:63998409-63998409
GRCh38: 8:63085850-63085850
26 TTPA NM_000370.3(TTPA):c.575G>A (p.Arg192His) SNV Likely pathogenic 9140 rs121917850 GRCh37: 8:63976853-63976853
GRCh38: 8:63064294-63064294
27 TTPA NM_000370.3(TTPA):c.2T>C (p.Met1Thr) SNV Likely pathogenic 189186 rs786204758 GRCh37: 8:63998579-63998579
GRCh38: 8:63086020-63086020
28 TTPA NM_000370.3(TTPA):c.557C>A (p.Ser186Ter) SNV Likely pathogenic 557235 rs1554605498 GRCh37: 8:63976871-63976871
GRCh38: 8:63064312-63064312
29 TTPA NM_000370.3(TTPA):c.1A>T (p.Met1Leu) SNV Likely pathogenic 557555 rs1408863841 GRCh37: 8:63998580-63998580
GRCh38: 8:63086021-63086021
30 TTPA NM_000370.3(TTPA):c.358G>A (p.Ala120Thr) SNV Conflicting interpretations of pathogenicity 65591 rs143010236 GRCh37: 8:63985494-63985494
GRCh38: 8:63072935-63072935
31 TTPA NM_000370.3(TTPA):c.36G>T (p.Pro12=) SNV Uncertain significance 724632 rs773911591 GRCh37: 8:63998545-63998545
GRCh38: 8:63085986-63085986
32 TTPA NM_000370.3(TTPA):c.552G>T (p.Thr184=) SNV Uncertain significance 557815 rs181109321 GRCh37: 8:63978463-63978463
GRCh38: 8:63065904-63065904
33 TTPA NM_000370.3(TTPA):c.-1C>T SNV Uncertain significance 557866 rs1349901379 GRCh37: 8:63998581-63998581
GRCh38: 8:63086022-63086022
34 TTPA NM_000370.3(TTPA):c.401G>A (p.Arg134Gln) SNV Uncertain significance 991274 GRCh37: 8:63978614-63978614
GRCh38: 8:63066055-63066055
35 TTPA NM_000370.3(TTPA):c.221A>G (p.Tyr74Cys) SNV Uncertain significance 991275 GRCh37: 8:63985631-63985631
GRCh38: 8:63073072-63073072
36 TTPA NM_000370.3(TTPA):c.177G>C (p.Arg59=) SNV Uncertain significance 991596 GRCh37: 8:63998404-63998404
GRCh38: 8:63085845-63085845
37 TTPA NM_000370.3(TTPA):c.166C>T (p.Leu56=) SNV Uncertain significance 991597 GRCh37: 8:63998415-63998415
GRCh38: 8:63085856-63085856
38 TTPA NM_000370.3(TTPA):c.123G>A (p.Pro41=) SNV Uncertain significance 991598 GRCh37: 8:63998458-63998458
GRCh38: 8:63085899-63085899
39 TTPA NM_000370.3(TTPA):c.452G>A (p.Arg151Gln) SNV Uncertain significance 363561 rs150710403 GRCh37: 8:63978563-63978563
GRCh38: 8:63066004-63066004
40 TTPA NM_000370.3(TTPA):c.661C>T (p.Arg221Trp) SNV Uncertain significance 65597 rs35916840 GRCh37: 8:63976767-63976767
GRCh38: 8:63064208-63064208
41 TTPA NM_000370.3(TTPA):c.*1598C>T SNV Uncertain significance 363532 rs886063059 GRCh37: 8:63972213-63972213
GRCh38: 8:63059654-63059654
42 TTPA NM_000370.3(TTPA):c.*806C>T SNV Uncertain significance 363546 rs752352118 GRCh37: 8:63973005-63973005
GRCh38: 8:63060446-63060446
43 TTPA NM_000370.3(TTPA):c.*452T>C SNV Uncertain significance 363552 rs886063066 GRCh37: 8:63973359-63973359
GRCh38: 8:63060800-63060800
44 TTPA NM_000370.3(TTPA):c.*292A>G SNV Uncertain significance 363554 rs886063067 GRCh37: 8:63973519-63973519
GRCh38: 8:63060960-63060960
45 TTPA NM_000370.3(TTPA):c.*1394A>G SNV Uncertain significance 363537 rs886063060 GRCh37: 8:63972417-63972417
GRCh38: 8:63059858-63059858
46 TTPA NM_000370.3(TTPA):c.*1481_*1484delATAA Microsatellite Uncertain significance 363534 rs773557348 GRCh37: 8:63972327-63972330
GRCh38: 8:63059768-63059771
47 TTPA NM_000370.3(TTPA):c.*1179_*1181delATA Microsatellite Uncertain significance 363540 rs548084272 GRCh37: 8:63972630-63972632
GRCh38: 8:63060071-63060073
48 TTPA NM_000370.3(TTPA):c.616G>A (p.Val206Ile) SNV Uncertain significance 363560 rs554118281 GRCh37: 8:63976812-63976812
GRCh38: 8:63064253-63064253
49 TTPA NM_000370.3(TTPA):c.*286C>G SNV Uncertain significance 363555 rs886063068 GRCh37: 8:63973525-63973525
GRCh38: 8:63060966-63060966
50 TTPA NM_000370.3(TTPA):c.*1368C>G SNV Uncertain significance 363538 rs553853197 GRCh37: 8:63972443-63972443
GRCh38: 8:63059884-63059884
Sources

Expression for Ataxia with Vitamin E Deficiency

About this section
Search GEO for disease gene expression data for Ataxia with Vitamin E Deficiency.
Sources

Pathways for Ataxia with Vitamin E Deficiency

About this section
Sources

GO Terms for Ataxia with Vitamin E Deficiency

About this section
Sources

Sources for Ataxia with Vitamin E Deficiency

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....